Details

Autor(en) / Beteiligte

• Ndhlovu, Lishomwa C
• Sinclair, Elizabeth
• Epling, Lorrie
• Tan, Qi Xuan
• Ho, Terence
• Jha, Aashish R
• Eccles-James, Ijeoma
• Tincati, Camilla
• Levy, Jay A
• Nixon, Douglas F
• Hecht, Frederick M
• Barbour, Jason D

Titel

IL-2 immunotherapy to recently HIV-1 infected adults maintains the numbers of IL-17 expressing CD4+ T (T(H)17) cells in the periphery

Ist Teil von

• Journal of clinical immunology, 2010-09, Vol.30 (5), p.681-692

Ort / Verlag

Netherlands

Erscheinungsjahr

2010

Quelle

MEDLINE

Beschreibungen/Notizen

• Little is known about the manipulation of IL-17 producing CD4+ T cells (T(H)17) on a per-cell basis in humans in vivo. Previous studies on the effects of IL-2 on IL-17 secretion in non-HIV models have shown divergent results. We hypothesized that IL-2 would mediate changes in IL-17 levels among recently HIV-1-infected adults receiving anti-retroviral therapy. We measured cytokine T cell responses to CD3/CD28, HIV-1 Gag, and CMV pp65 stimulation, and changes in multiple CD4+ T cell subsets. Those who received IL-2 showed a robust expansion of naive and total CD4+ T cell counts and T-reg counts. However, after IL-2 treatment, the frequency of T(H)17 cells declined, while counts of T(H)17 cells did not change due to an expansion of the CD4+ naïve T cell population (CD27+CD45RA+). Counts of HIV-1 Gag-specific T cells declined modestly, but CMV pp65 and CD3/CD28 stimulated populations did not change. Hence, in contrast with recent studies, our results suggest IL-2 is not a potent in vivo regulator of T(H)17 cell populations in HIV-1 disease. However, IL-2-mediated T-reg expansions may selectively reduce responses to certain antigen-specific populations, such as HIV-1 Gag.